ClinicalTrials.gg
RecruitingNCT06613009Updated Feb 11, 2025

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

A Phase 1 interventional study of IBI3009 in Small Cell Lung Cancer, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
89th of 333
190 · median 63
Started
2024
with 51 others
Phase 1
43 of 365
24 open now
Primary completion
2027-08
later than 115 of 214 live
Registered
242nd of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 89th largest by planned enrollment of the 333 interventional ones that give a count, is one of 52 that started in 2024, is one of 43 in phase 1, reaches primary completion later than 115 of the 214 other live ones, and was the 242nd registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 366 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 266 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants have the ability to understand and give written for participation in this trial, including all evaluations and procedures as specified by this protocol;
  2. Male or female subjects ≥ 18 years old. For Part 1, age ≥18 years and ≤75 years;
  3. (ECOG) Performance Status score of 0-1;
  4. Minimum of ≥ 12 weeks;
  5. Adequate organ function confirmed at screening period;
  6. or cytologically confirmed unresectable, or Extensive-Stage small cell lung cancer (SCLC).

Exclusion criteria

Exclusion Criteria

  1. Participating in any other interventional clinical research except observational (non-interventional) study or in the follow-up phase of an interventional study;
  2. Has adverse reactions resulting from previous anti-tumor therapies, which have not resolved to Grade 0 or 1 toxicity according to v5.0 (except for alopecia, fatigue, pigmentation and other conditions with no safety risk according to investigator's discretion) prior to the first dose of the study drug;
  3. Known allergies, , or intolerance to IBI3009 or its ;
  4. Undergone major surgery (Craniotomy, thoracotomy or laparotomy, and other surgery according to investigator's discretion, excluding needle ) within 4 weeks prior to the first dose of the study drug, or who are expected to undergo major surgery during the study period, or who have severe unhealed wounds, trauma, ulcers, etc.;
  5. Women who are pregnant, have positive results in pregnancy test or are lactating;
  6. Not eligible to participate in this study at the discretion of the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    IBI3009

    Drug: IBI3009

Interventions

  • DrugIBI3009

    Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)

06

What researchers measure

Primary outcomes

  1. Numbers of subjects with adverse events

    defined as any untoward medical occurrence, whether or not there is a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed

    Time frame: Up to 3 years

  2. Number of subjects with clinically significant changes in physical examination results

    Clinically significant abnormal physical examination findings reported by the investigator.

    Time frame: Up to 3 years

  3. Number of subjects with clinically significant changes in electrocardiogram

    Clinically significant abnormal electrocardiogram findings reported by the investigator.

    Time frame: Up to 3 years

  4. Number of subjects with clinically significant changes in vital signs

    Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure

    Time frame: Up to 3 years

  5. Dose limiting toxicities (DLTs)

    Dose limiting toxicities (DLTs) to establish MTD and/or RDE.

    Time frame: Up to 28 days

Secondary outcomes

  1. area under the curve (AUC)

    area under the curve (AUC) of single and multiple doses of IBI3009

    Time frame: Up to 3 years

  2. maximum concentration (Cmax)

    maximum concentration (Cmax) of single and multiple doses of IBI3009

    Time frame: Up to 3 years

  3. time to maximum concentration (Tmax)

    time to maximum concentration (Tmax) of single and multiple doses of IBI3009

    Time frame: Up to 3 years

  4. clearance (CL)

    clearance (CL) of single and multiple doses of IBI3009

    Time frame: Up to 3 years

  5. apparent volume of distribution (V)

    apparent volume of distribution (V) of single and multiple doses of IBI3009

    Time frame: Up to 3 years

  6. half-life (t1/2)

    half-life (t1/2) of IBI3009 to the last administration of IBI3009

    Time frame: Up to 3 years

  7. anti-drug antibody (ADA)

    Incidence and characterization of anti-drug antibody (ADA).

    Time frame: Up to 3 years

  8. objective response rate (ORR)

    objective response rate (ORR) as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  9. duration of response (DoR)

    duration of response (DoR) as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  10. time to response (TTR)

    time to response (TTR) as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  11. progression free survival (PFS)

    as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  12. overall survival (OS)

    OS is defined as the time from the date of first dose of study drug until the date of death from any cause.

    Time frame: Through out the study (an average of 3 years)

07

Study locations

4 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Aug 2027, 32 months after the start.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 32 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2024
First posted
Sep 25, 2024
StartActual
Dec 30, 2024
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06613009
Responsible party
Sponsor
First posted
Sep 25, 2024
Start date
Dec 30, 2024
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Feb 11, 2025

Study contacts

Lue Shen
Contact
lue.shen@innoventbio.com
+86 18507159591

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion